Sarah Cannon Research Institute clinical trials
Also known as SCRI.
Part of McKesson Corporation, which holds 51% as of 2022-10-31. Source
The registry lists 29 studies whose lead sponsor is Sarah Cannon Research Institute or the company grouped under it. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated May 18, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 29studies on the registry
- 1open to participants now
- 1reach primary completion within a year
Get an email when these change. Save the Sarah Cannon Research Institute studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs Sarah Cannon Research Institute’s studies test, most studies first; none is open now — 28 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Cetuximab1 in phase 30 open · 4
- 0 open · 3
- 0 open · 3
- 0 open · 2
- 0 open · 2
- 0 open · 2
- 0 open · 2
- 0 open · 1
- 0 open · 1
- 0 open · 1
Show 18 moreShow fewer
Coming up
1 of Sarah Cannon Research Institute’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- 1SSep
- OOct
- NNov
The study
- Sep 2027MYLUNG Consortium Study Protocol 2NCT05644808
Add it to your calendar (.ics) → With an account.
All 29 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 507
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 7 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sarah Cannon Research Institute.
- US Oncology Research29 studies →Acquired — became part of Sarah Cannon Research Institute, Oct 31, 2022 · source ↗
Something wrong?
Focus areas
Conditions Sarah Cannon Research Institute leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- MYLUNG Consortium Part 3: Observational StudyRecruitingNCT05885698
Sponsor listed in the registry: US Oncology Research · First submitted after US Oncology Research became part of Sarah Cannon Research Institute
- MYLUNG Consortium Study Protocol 2Active, not recruitingNCT05644808
Sponsor listed in the registry: US Oncology Research · First submitted after US Oncology Research became part of Sarah Cannon Research Institute
- PhII ICb With/Without Erbitux in MBC PtsActive, not recruitingNCT00248287Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04782687Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast CancerActive, not recruitingNCT03379428Phase 1/2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerCompletedNCT02187991Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- TAC Versus TC for Adjuvant Breast CancerCompletedNCT00493870Phase 3
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast CancerTerminatedNCT02229149Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by EverolimusCompletedNCT02229136Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- STAR Cape+BKM120 MBC With Brain MetCompletedNCT02000882Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOXTerminatedNCT02425683Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal CancerCompletedNCT00252564Phase 3
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Vidaza to Restore Hormone Thx ProstateCompletedNCT00384839Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Phase II Sunitinib Prog Met AIPCCompletedNCT00599313Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Synera Venipuncture PainCompletedNCT01744197Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Sunitinib Non Small Cell Lung Cancer Patients Over 70CompletedNCT00864721Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)CompletedNCT00661492Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Ixabepilone + Carboplatin Metastatic Breast CancerCompletedNCT01075100Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Docetaxel+Oxali+/-Cetux Met Gastric/GEJCompletedNCT00517829Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia PatientsCompletedNCT00254163Phase 3
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Adj TC + Herceptin Early Stage Breast CancerCompletedNCT00493649Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Ph2 Gem/Nov/Rituxan Rel/Ref MantleCellCompletedNCT00656084Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Doxil & Carboplatin Plus HER2+ in Metastatic Breast CancerCompletedNCT00303108Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Pre-op Rectal ChemoRad +/- CetuximabCompletedNCT00527111Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Gemzar, Cisp, Sunitinib Urothelial CaCompletedNCT00821327Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic CancerStatus unknownNCT01934634Phase 1
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)CompletedNCT01909362
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Triple Negative Breast Cancer Biomarker StudyCompletedNCT01111175
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute
- Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's LymphomaTerminatedNCT00250861Phase 2
Sponsor listed in the registry: US Oncology Research · First submitted before US Oncology Research became part of Sarah Cannon Research Institute